Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MATERNAL BLOOD TEST MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL MATERNAL BLOOD TEST MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MATERNAL BLOOD TEST MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL MATERNAL BLOOD TEST MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 GLOBAL MATERNAL BLOOD TEST MARKET, BY PRODUCT AND SERVICES
16.1 OVERVIEW
16.2 PRODUCT
16.2.1 TEST KITS
16.2.1.1. NIPT KITS
16.2.1.1.1. SINGLE-GENE DISORDER KITS
16.2.1.1.2. MULTI-GENE PANEL KITS
16.2.1.1.3. CFDNA-BASED KITS
16.2.1.2. CARRIER SCREENING KITS
16.2.1.2.1. ETHNICITY-SPECIFIC CARRIER SCREENING KITS
16.2.1.2.2. EXPANDED CARRIER SCREENING KITS
16.2.1.3. BIOCHEMICAL SCREENING KITS
16.2.1.3.1. TRIPLE MARKER KITS
16.2.1.3.2. QUADRUPLE MARKER KITS
16.2.1.4. COMBINED SCREENING KITS
16.2.1.4.1. FIRST TRIMESTER COMBINED KITS
16.2.1.4.2. SEQUENTIAL SCREENING KITS
16.2.1.5. RAPID TEST KITS
16.2.2 INSTRUMENTS
16.2.2.1. DIAGNOSTIC DEVICES
16.2.2.1.1. SEQUENCING MACHINES (NGS-BASED AND SANGER SEQUENCING)
16.2.2.1.2. PCR DEVICES (REAL-TIME AND DIGITAL PCR)
16.2.2.1.3. FLUORESCENCE IN SITU HYBRIDIZATION (FISH) SYSTEMS
16.2.2.2. AUTOMATION PLATFORMS
16.2.2.2.1. ROBOTIC LIQUID HANDLERS FOR HIGH-THROUGHPUT TESTING
16.2.2.2.2. SAMPLE PREPARATION INSTRUMENTS
16.2.2.2.3. OTHERS
16.2.2.3. IMMUNOASSAY SYSTEMS
16.2.2.3.1. ELISA READERS
16.2.2.3.2. CHEMILUMINESCENCE ANALYZERS
16.2.3 CONSUMABLES
16.2.3.1. COLLECTION MATERIALS
16.2.3.1.1. SPECIALIZED BLOOD COLLECTION TUBES FOR CFDNA STABILITY
16.2.3.1.2. SERUM/PLASMA COLLECTION SYSTEMS
16.2.3.2. REAGENTS AND BUFFERS
16.2.3.2.1. PCR REAGENTS
16.2.3.2.2. ANTIBODY REAGENTS FOR BIOCHEMICAL ASSAYS
16.2.3.3. SAMPLE PREPARATION CONSUMABLES
16.2.3.3.1. DNA/RNA EXTRACTION KITS
16.2.3.3.2. MICROARRAY PREPARATION KITS
16.2.3.4. SINGLE-USE ITEMS
16.2.3.4.1. DISPOSABLE PIPETTES
16.2.3.4.2. SPECIALIZED REACTION PLATES
16.3 SERVICES AND SOFTWARE
17 GLOBAL MATERNAL BLOOD TEST MARKET, BY TEST TYPE
17.1 OVERVIEW
17.2 NON-INVASIVE PRENATAL TESTING (NIPT)
17.2.1 CELL-FREE DNA (CFDNA) TESTING
17.2.2 CHROMOSOMAL ANEUPLOIDY SCREENING
17.2.3 MICRODELETIONS AND MICRODUPLICATIONS TESTING
17.3 CARRIER SCREENING TESTS
17.3.1 SINGLE-GENE DISORDERS
17.3.2 MULTI-GENE PANELS
17.4 BIOCHEMICAL SCREENING
17.4.1 TRIPLE MARKER TESTS
17.4.2 QUADRUPLE MARKER TESTS
17.5 COMBINED FIRST TRIMESTER SCREENING
17.6 MATERNAL SERUM SCREENING
17.7 OTHERS
18 GLOBAL MATERNAL BLOOD TEST MARKET, BY TECHNOLOGY
18.1 OVERVIEW
18.2 POLYMERASE CHAIN REACTION (PCR)
18.3 NEXT-GENERATION SEQUENCING (NGS)
18.4 MICROARRAY TECHNOLOGY
18.5 IMMUNOASSAYS
18.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
18.7 OTHERS
19 GLOBAL MATERNAL BLOOD TEST MARKET, BY APPLICATION
19.1 OVERVIEW
19.2 FETAL ANEUPLOIDY DETECTION
19.2.1 DOWN SYNDROME (TRISOMY 21)
19.2.2 EDWARDS SYNDROME (TRISOMY 18)
19.2.3 PATAU SYNDROME (TRISOMY 13)
19.3 GENDER DETERMINATION
19.4 SCREENING FOR MONOGENIC DISORDERS
19.5 DETECTION OF MICRODELETIONS/MICRODUPLICATIONS
19.6 RHD AND BLOOD GROUP TYPING
19.7 SCREENING FOR PRE-ECLAMPSIA AND GESTATIONAL DIABETES
19.8 OTHERS
20 GLOBAL MATERNAL BLOOD TEST MARKET, BY SCREENING TYPE
20.1 OVERVIEW
20.2 ROUTINE SCREENING
20.3 HIGH-RISK PREGNANCY SCREENING
20.3.1 ADVANCED MATERNAL AGE
20.3.2 FAMILY HISTORY OF GENETIC DISORDERS
20.3.3 RECURRENT PREGNANCY LOSS
21 GLOBAL MATERNAL BLOOD TEST MARKET, BY TRIMESTER
21.1 OVERVIEW
21.2 FIRST TRIMESTER
21.3 SECOND TRIMESTER
21.4 THIRD TRIMESTER
22 GLOBAL MATERNAL BLOOD TEST MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.3 DIAGNOSTIC LABORATORIES
22.4 MATERNITY CLINICS
22.5 HOME CARE SETTINGS
22.6 RESEARCH & ACADEMIC INSTITUTIONS
22.7 OTHERS
23 GLOBAL MATERNAL BLOOD TEST MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDERS
23.3 RETAIL SALES
23.3.1 ONLINE SALES
23.3.2 OFFLINES SALES
23.4 OTHERS
24 GLOBAL MATERNAL BLOOD TEST MARKET , BY GEOGRAPHY
GLOBAL MATERNAL BLOOD TEST MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 ASIA-PACIFIC
24.1.1 JAPAN
24.1.2 CHINA
24.1.3 SOUTH KOREA
24.1.4 INDIA
24.1.5 AUSTRALIA
24.1.6 SINGAPORE
24.1.7 THAILAND
24.1.8 MALAYSIA
24.1.9 INDONESIA
24.1.10 PHILIPPINES
24.1.11 REST OF ASIA-PACIFIC
24.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL MATERNAL BLOOD TEST MARKET , COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL MATERNAL BLOOD TEST MARKET , SWOT AND DBMR ANALYSIS
27 GLOBAL MATERNAL BLOOD TEST MARKET , COMPANY PROFILE
27.1 BIO-RAD LABORATORIES, INC.
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 ABBOTT
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 SIEMENS HEALTHINEERS AG
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 DANAHER
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 DIASORIN S.P.A.
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 ALPCO
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 BIOASSAY SYSTEMS
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 DIAZYME LABORATORIES, INC
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 ABNOVA CORPORATION
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 DRG INSTRUMENTS GMBH
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 EKF DIAGNOSTICS HOLDINGS PLC
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 ETHOS BIOSCIENCES, INC.
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 MEDIPAN GMBH
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 MERCK KGAA
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 MONOBIND INC.
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 ORGENTEC DIAGNOSTIKA GMBH
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 ORTHO CLINICAL DIAGNOSTICS
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 PTS DIAGNOSTICS (A SUBSIDIARY OF SANNUO BIOSENSOR CO., LTD.)
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 TOSOH CORPORATION
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 F. HOFFMANN-LA ROCHE AG
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 NOVO NORDISK A/S
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 ARKRAY INC
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 ASCENSIA DIABETES CARE
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 LIFESCAN IP HOLDING, LLC
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 DEXCOM, INC.
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 MEDTRONIC
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
27.28 B. BRAUN MELSUNGEN AG
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPMENTS
27.29 TERUMO CORPORATION
27.29.1 COMPANY OVERVIEW
27.29.2 REVENUE ANALYSIS
27.29.3 GEOGRAPHIC PRESENCE
27.29.4 PRODUCT PORTFOLIO
27.29.5 RECENT DEVELOPMENTS
27.3 ACON LABORATORIES, INC.
27.30.1 COMPANY OVERVIEW
27.30.2 REVENUE ANALYSIS
27.30.3 GEOGRAPHIC PRESENCE
27.30.4 PRODUCT PORTFOLIO
27.30.5 RECENT DEVELOPMENTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
